Display options
Cite
Nayak S, Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol. 2008;53(1):2-8doi: 10.4103/0019-5154.39732.
Nayak, S., & Acharjya, B. (2008). Adverse cutaneous drug reaction. Indian journal of dermatology, 53(1), 2-8. https://doi.org/10.4103/0019-5154.39732
Nayak, Surajit, and Acharjya, Basanti. "Adverse cutaneous drug reaction." Indian journal of dermatology vol. 53,1 (2008): 2-8. doi: https://doi.org/10.4103/0019-5154.39732
Nayak S, Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol. 2008 Jan;53(1):2-8. doi: 10.4103/0019-5154.39732. PMID: 19967009; PMCID: PMC2784579.
Copy Download .nbib Format: NLM
Share it on

Indian J Dermatol. 2008 Jan;53(1):2-8. doi: 10.4103/0019-5154.39732.

Adverse cutaneous drug reaction.

Indian journal of dermatology

Surajit Nayak, Basanti Acharjya

Affiliations

  1. Department of Skin and VD, MKCG Medical College and Hospital, Berhampur, Orissa, India. [email protected]

PMID: 19967009 PMCID: PMC2784579 DOI: 10.4103/0019-5154.39732

Abstract

In everyday clinical practice, almost all physicians come across many instances of suspected adverse cutaneous drug reactions (ACDR) in different forms. Although such cutaneous reactions are common, comprehensive information regarding their incidence, severity and ultimate health effects are often not available as many cases go unreported. It is also a fact that in the present world, almost everyday a new drug enters market; therefore, a chance of a new drug reaction manifesting somewhere in some form in any corner of world is unknown or unreported. Although many a times, presentation is too trivial and benign, the early identification of the condition and identifying the culprit drug and omit it at earliest holds the keystone in management and prevention of a more severe drug rash. Therefore, not only the dermatologists, but all practicing physicians should be familiar with these conditions to diagnose them early and to be prepared to handle them adequately. However, we all know it is most challenging and practically difficult when patient is on multiple medicines because of myriad clinical symptoms, poorly understood multiple mechanisms of drug-host interaction, relative paucity of laboratory testing that is available for any definitive and confirmatory drug-specific testing. Therefore, in practice, the diagnosis of ACDR is purely based on clinical judgment. In this discussion, we will be primarily focusing on pathomechanism and approach to reach a diagnosis, which is the vital pillar to manage any case of ACDR.

Keywords: ACDR; Steven Johnson syndrome; adverse drug reactions; toxic epidermal necrolysis

References

  1. J Invest Dermatol. 1995 Jul;105(1 Suppl):95S-98S - PubMed
  2. Arch Dermatol. 2001 Apr;137(4):511-2 - PubMed
  3. J Clin Pharmacol. 2000 Oct;40(10):1093-101 - PubMed
  4. J Am Acad Dermatol. 1996 Sep;35(3 Pt 1):458-61 - PubMed
  5. Indian J Dermatol Venereol Leprol. 2004 Jan-Feb;70(1):20-4 - PubMed
  6. N Engl J Med. 1994 Nov 10;331(19):1272-85 - PubMed
  7. Indian J Dermatol Venereol Leprol. 1999 Jan-Feb;65(1):14-7 - PubMed
  8. Pharmacol Rev. 2001 Sep;53(3):357-79 - PubMed
  9. J Allergy Clin Immunol. 2000 Jun;105(6 Pt 2):S637-44 - PubMed
  10. Acta Derm Venereol. 1984;64(4):320-4 - PubMed
  11. Clin Exp Allergy. 2000 Jun;30(6):847-55 - PubMed
  12. Ann Allergy Asthma Immunol. 1995 Feb;74(2):167-70 - PubMed
  13. JAMA. 1997 Dec 10;278(22):1895-906 - PubMed
  14. Natl Med J India. 2000 Jan-Feb;13(1):16-8 - PubMed
  15. J Postgrad Med. 2001 Apr-Jun;47(2):95-9 - PubMed
  16. Drug Saf. 1991 Nov-Dec;6(6):431-49 - PubMed
  17. JAMA. 1987 Nov 27;258(20):2891-9 - PubMed
  18. JAMA. 1998 Apr 15;279(15):1200-5 - PubMed
  19. Ann Allergy Asthma Immunol. 1999 Dec;83(6 Pt 3):665-700 - PubMed
  20. Arch Dermatol. 2001 Jun;137(6):765-70 - PubMed
  21. Clin Geriatr Med. 2002 Feb;18(1):21-42 - PubMed

Publication Types